Skip to Content

Deflazacort Dosage

Medically reviewed on July 28, 2017.

Applies to the following strengths: 6 mg; 18 mg; 30 mg; 36 mg; 22.75 mg/mL

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Muscular Dystrophy

0.9 mg/kg orally once a day

Comments:
-If tablets are used, round up to the nearest possible dose
-If oral suspension is used, round up to the nearest tenth of a milliliter (mL).
-If this drug is administered for more than a few days, do not abruptly discontinue.
-Dose modifications are recommended for use with CYP450 3A4 inhibitors and inducers (see dose adjustments).

Use: Treatment of Duchenne muscular dystrophy.

Usual Pediatric Dose for Muscular Dystrophy

5 years or older: 0.9 mg/kg orally once a day

Comments:
-If tablets are used, round up to the nearest possible dose
-If oral suspension is used, round up to the nearest tenth of a milliliter (mL).
-If this drug is administered for more than a few days, do not abruptly discontinue.
-Dose modifications are recommended for use with CYP450 3A4 inhibitors and inducers (see dose adjustments).

Use: Treatment of Duchenne muscular dystrophy.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Mild or moderate impairment: No adjustment recommended
Severe impairment: Data not available; no dosing recommendation can be provided

Dose Adjustments

Moderate or Strong CYP450 3A4 Inhibitors: Give one-third of the recommended dosage

Moderate or Strong CYP450 3A4 Inducers: Avoid use

Do not take with grapefruit juice

Precautions

Safety and efficacy have not been established in patients younger than 5 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Take with or without food
-Do not take with grapefruit juice

-Tablets: May be taken whole or crushed; if crushed, may mix with applesauce and take immediately after mixing

-Oral suspension:
-Shake well before measuring dose; use provided measuring device to ensure accurate dosing
-Slowly add measured dose into 3 or 4 ounces of juice or milk and mix well; administer immediately
-Wash dispenser after each use

Storage requirements:
Oral Suspension:
-Store upright at room temperature; discard 1 month after first opening

General:
-Do not stop therapy abruptly; gradually reduce dose if the drug has been administered for more than a few days.
-In clinical trials, patients receiving 1.2 mg/kg/day demonstrated small additional benefits but had a greater incidence of adverse reactions; the use of this dose is not recommended.
-This corticosteroid is derived from prednisolone; deflazacort 6 mg has approximately the same antiinflammatory potency as 5 mg of prednisone or prednisolone.

Monitoring:
-Monitor growth velocity and development in pediatric patients
-Monitor intraocular pressure if therapy is continued for more than 6 weeks; regular eye exams should be encouraged
-Routine laboratory studies (including 2-hour postprandial blood glucose and serum potassium), blood pressure, weight, bone mineral density, and chest x-rays should be performed at regular intervals for patients on long-term corticosteroid therapy
-Monitor for hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and hyperglycemia with chronic steroid users

Patient advice:
-Patients should understand that this drug should not be stopped abruptly or without medical advice; additionally, all healthcare professionals providing care should be informed of current and past corticosteroid use.
-Patients should understand that during times of stress, such as surgery or infection, additional supplementation doses may be necessary; they should discuss with their healthcare professional whether they need to carry a medical identification card that identifies their corticosteroid use.
-Patients on immunosuppressant doses of corticosteroids should understand that a greater risk of infection exists; they should avoid exposure to chickenpox or measles and if exposed, they should consult their healthcare professional promptly.
-Patients should check with their healthcare provider before receiving any vaccinations.
-Patients should be advised of common adverse reactions including changes in glucose tolerance, high blood pressure, behavioral/mood changes, increased appetite, and weight gain.
-Patients should understand the risks of prolonged use including decreased bone mineral density and ophthalmic effects and that regular monitoring is necessary.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide